查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1190814

面部注射剂市场 - COVID-19 的增长、趋势、影响和预测 (2023-2028)

Facial Injectables Market - Growth, Trends , , and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 113 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

面部植入物市场预计在预测期内（2022 年至 2027 年）的复合年增长率为 12.2%。

COVID-19 的爆发减少了公共出行，推迟了非立即手术和筛查计划以减轻医护人员的负担，并对治疗和手术健康产生了重大影响。我正在给予 例如，根据 2020 年 5 月发表的论文“因 COVID-19 大流行而取消择期手术：全球预测模型为手术恢復计划提供信息”，COVID-19 导致医院服务中断的高峰期为 12几週内，2020 年全球约有 2804 万例择期手术被取消或推迟。 此外，全球范围内大量的 COVID-19 病例最初对整容手术率产生了短期影响。 然而，整容手术预计将在 2021 年和 2022 年在全球范围内恢復，有望在不久的将来引领市场。

此外，审美意识的提高和整容手术数量的增加、具有成本效益的面部植入物的推出、人口老龄化等是推动市场增长的主要因素。

化妆品行业在过去十年中经历了繁荣。 特别是，美学吸引力的激增和先进美容程序的可用性增加了非手术程序的总数，例如注射抗皱剂和真皮填充剂。 这一趋势主要归功于技术优势，例如更短的恢復时间、更低的感染风险、更少的出血和更低的总体手术成本。 例如，根据国际美容整形外科学会（ISAPS）发布的《2020 年全球调查结果》报告，2020 年共进行了 10,129,528 例整容手术。 2020 年排名靠前的非手术手术包括羟基磷灰石钙 (222,785)、聚-L 乳酸 (121,087)、肉毒桿菌毒素和透明质酸。

此外，老年人口的持续增加也推动了市场的增长。 例如，根据世界卫生组织的数据，到 2030 年，地球上将有六分之一的人超过 60 岁。 预计 60 岁及以上的人口将从 2020 年的 10 亿增长到 2050 年的 14 亿。 到 2050 年，世界上 60 岁及以上的人口将达到 21 亿。 从 2020 年到 2050 年，80 岁及以上的人口数量预计将增加两倍，达到 4.26 亿。 这样，老年人中老年人美容护理的趋势有望在不久的将来推动市场增长。

市场参与者正在采取各种策略，例如产品发布、开发、合作伙伴关係、收购和扩张，以增加他们的市场份额。 例如，2021年9月，Aesthetic Innovators推出了比传统填充剂产品体积更小的透明质酸（HA）真皮填充剂“迈力”，以及业界首款体胶原刺激填充剂“兰露玛”。勾选世界。

因此，上述因素预计将在预测期内推动市场增长。 然而，可用产品的副作用限制了采用，缺乏支持整容手术的报销政策可能会在不久的将来阻碍市场增长。

面部注射市场趋势

透明质酸部分预计在预测期内占有很大份额

透明质酸细分市场预计将在未来几年主导真皮填充剂细分市场。 透明质酸部分增长的一个因素是它能够保持皮肤水分，使其看起来更健康。 这种水分结合特性有助于强化和保留使面部皮肤丰盈的重要水分。 透明质酸具有增加水合作用、改善弹性、逆转自由基损伤和防止紫外线损伤的显着益处。 因此，透明质酸的这些好处可能会在预测期内推动该细分市场的增长。

根据国际美容整形外科协会 2020 年世界调查于 2021 年 12 月发布的结果，透明质酸被列为非手术美容程序的前五名。 此外，据报导，2020 年共进行了 4,053,016 次透明质酸治疗。 全球执行的大量手术创造了对创新产品的需求，推动了这一领域的增长。

此外，市场参与者正在采取各种策略，例如产品发布、开发、协作、合作伙伴关係、收购和扩张，以增加他们的市场份额。 例如，2020 年 6 月，艾伯维公司（Allergan Plc）获得美国食品药品监督管理局（FDA）的批准，用于 21 岁及以上成人的 JUVEDERM VOLUMA XC 增强颌骨。 同样在 2020 年 8 月，Revance 推出了 RHA（弹性透明质酸）填充剂系列。 弹性透明质酸填充剂旨在适应面部运动，是美容实践产品系列的第一步。

因此，由于上述因素，研究部门有望在预测期内实现增长。

北美主导市场，预计在预测期内也会如此

推动北美地区市场增长的因素包括对整容手术的高度认识、整容手术的技术进步、主要市场参与者的存在、老年人口的增加以及对非侵入性整容手术的需求。例如

根据美国整形外科医生协会 (ASPS) 的数据，由于 2020 年的 COVID-19，整形外科医生平均停止进行择期手术的时间为 8.1 週，即一年中的 15%，这意味着手术次数。 此外，在 2020 年的住院订单中，微创整容手术比外科手术略有下降（16% 对 14%），这是四年来的首次下降。 这种情况对大流行早期的市场增长率产生了不利影响。 然而，由于选择性手术的恢復和美容中心的重新开放，预计该地区的市场增长将恢復到大流行前的水平。

同样，在加拿大，人口老龄化正在推动市场增长。 根据加拿大统计局 2021 年人口普查，65 岁及以上人口约为 7,021,430 人，其中男性 3,224,680 人，女性 3,796,750 人。 随着这个年龄段的老年人对美容护理的兴趣增加，预计对美容填料的需求将会增长。

美国大公司的进驻和新产品进入市场使我们在全球市场上具有竞争优势。 2020年1月， Revance Therapeutics 宣布完成一项变革性的美学投资组合交易，签署了美国食品药品监督管理局批准的 Teoxane SA 皮肤填充剂的独家美国分销协议。 TEOXANE SA RHA 产品组合是首批获得 FDA 批准的用于动态皱纹矫正的真皮填充剂之一。

因此，由于上述因素，预计该地区在预测期内将呈现快速增长。

面部植入物市场竞争分析

面部注射市场的竞争很低。 市场上的主要参与者正在製定合作和产品发布策略，以满足未满足的美容需求。 因此，随着医生可以使用新的和改进的选择，面部植入物的市场正在扩大。 公司还专注于扩大其在新兴市场的影响力并与分销商保持牢固的关係。 市场参与者包括 AbbVie Inc. (Allergan Plc)、Ipsen SA、Medytox Inc.、Merz Pharma、Sinclair Pharma Plc。

其他福利。

  • Excel 格式的市场预测 (ME) 表
  • 3 个月的分析师支持

内容

第1章介绍

  • 研究假设和市场定义
  • 调查范围

第2章研究方法论

第 3 章执行摘要

第4章市场动态

  • 市场概览
  • 市场驱动因素
    • 美容意识的提高和整形手术的增加
    • 经济高效的面部注射简介
    • 人口老龄化
  • 市场製约因素
    • 可用产品的副作用限制了采用
    • 缺乏支持整容手术的报销政策
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：百万美元）

  • 按类型
    • 抗皱剂
      • 肉毒桿菌毒素
    • 真皮填充剂
      • 胶原蛋白
      • 透明质酸
      • 脂肪注射
      • 聚乳酸
      • 聚甲基丙烯酸甲酯微球 (PMMA)
      • 羟基磷灰石
      • 其他真皮填充剂（例如聚烷基□亚胺）
  • 通过使用
    • 面部线条校正
    • 唇部加固
    • 整容
    • 痤疮疤痕治疗
    • 脂肪代谢障碍的治疗
    • 其他用途（下巴整形、耳垂年轻化等）
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东和非洲
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章竞争格局

  • 公司简介
    • AbbVie Inc（Allergan Plc）
    • Anika Therapeutics Inc.
    • Ipsen SA
    • Medytox Inc.
    • Merz Pharma
    • Galderma Pharma SA
    • Sanofi SA
    • Sinclair Pharma Plc
    • Suneva Medical Inc.
    • Alphaeon Corporation（Teoxane Laboratories）
    • Bloomage Biotechnology（Laboratories Vivacy SAS）
    • SciVision Biotech Inc.

第7章 市场机会与今后动向

简介目录
Product Code: 64173

The Facial Injectables market is expected to register a CAGR of 12.2% during the forecast period (2022-2027).

The outbreak of COVID-19 resulted in decreased public mobility and has also impacted therapeutic and surgical health significantly, as the surgical procedures and screening programs, which were non-immediate, were postponed in order to decrease the burden on healthcare professionals. For instance, according to the article titled ''Elective surgery cancellations due to the COVID-19 pandemic: global predictive modeling to inform surgical recovery plans'' published in May 2020, based on 12 weeks of peak disruption to hospital services due to COVID-19, around 28.4 million elective surgeries worldwide were canceled or postponed in 2020. In addition, a large number of cases of COVID-19 across the globe had a short-term impact on surgical rates of cosmetic procedures in the initial outbreak phase. However, owing to the resumption of elective services and cosmetic procedures around the world in 2021 and 2022, the market is anticipated to gain traction in the near future.

Furthermore, the rising aesthetic consciousness and the number of cosmetic procedures, the introduction of cost-effective facial injectables, and the aging population are some of the major factors propelling the market's growth.

The cosmetic industry has witnessed a boom over the past decade. In particular, there has been an increase in the total number of non-surgical procedures, such as injections of wrinkle relaxers and dermal fillers, due to the surge in aesthetic appeal and availability of highly advanced aesthetic procedures. This trend is primarily due to the advantages of technology, such as low recovery time, less risk of infections, no blood loss, and the overall reduction in procedural costs. For instance, according to the International Society of Aesthetic Plastic Surgery (ISAPS) published global survey results 2020 report, 10,129,528 cosmetic surgical procedures were performed in 2020. The top non-surgical procedures in 2020 include Calcium Hydroxylapatite (222,785) and Poly-L-Lactic Acid (121,087) and others such as Botulinum toxin and hyaluronic acid.

In addition, there is a consistent rise in the geriatric population, which helps to boost the market's growth. For instance, according to the World Health Organization, by 2030, 1 out of every six people on the planet will be 60 years old or older. The number of people aged 60 and up is expected to rise from 1 billion in 2020 to 1.4 billion by 2050. By 2050, the global population of people aged 60 and above will reach 2.1 billion. Between 2020 and 2050, the number of people aged 80 and above is expected to triple, reaching 426 million. Thus, the growing trend with respect to geriatric aesthetics in the older population is likely to boost the market's growth in the near future.

The market players are adopting various strategies, such as product launches, developments, collaborations, partnerships, acquisitions, and expansions, to increase market share. For instance, in September 2021, Aesthetics Innovators launched two new injectables into the aesthetics sphere MaiLi, a hyaluronic acid (HA) dermal filler that uses less product than traditional fillers; and Lanluma, an industry-first collagen-stimulating filler for the body.

Thus, the abovementioned factors are likely to drive market growth over the forecast period. However, the side effects of available products, which limit adoption, and a lack of reimbursement policies supporting cosmetic procedures may impede market growth in the near future.

Facial Injectables Market Trends

Hyaluronic Acid Segment is Expected to Hold Significant Share Over the Forecast Period

The hyaluronic acid sub-segment is anticipated to dominate the dermal fillers segment over the coming years. Some of the factors responsible for hyaluronic acid segment growth include its ability to store moisture in the skin, thus making the skin look healthier. This moisture-binding characteristic helps enhance and maintain the vital moisture responsible for the plumpness of the facial skin. Hyaluronic acid has significant benefits as it increases hydration, improves elasticity, and reverses free radical damage that protects from UV damage. Thus, such advantages of hyaluronic acid are likely to boost the segment's growth over the forecast period.

According to the International Society of Aesthetic Plastic Surgery, Global Survey 2020 results, released in December 2021, hyaluronic acid is listed among the top 5 non-surgical aesthetic procedures. It also reported that a total of 4,053,016 hyaluronic acid procedures were performed in the year 2020. Such a high number of procedures performed globally creates a need for innovative products and thus drives the growth of the segment.

Moreover, the market players are adopting various strategies, such as product launches, developments, collaborations, partnerships, acquisitions, and expansions, to increase their market share. For instance, in June 2020, AbbVie Inc. (Allergan Plc) received approval from United States Food and Drug Administration (FDA) for JUVEDERM VOLUMA XC for the augmentation of the chin region in adults over the age of 21. In addition, in August 2020, Revance launched the RHA (resilient hyaluronic acid) collection of fillers. The resilient hyaluronic acid fillers are designed to adapt to facial dynamics and represent the first step in a line of products for aesthetic practices.

Thus, owing to the abovementioned factors, the studied segment is expected to project growth over the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period

Some of the factors driving the market growth in the North American region include higher awareness about aesthetic surgical procedures; technological advancements in cosmetic procedures; the presence of key market players; the increasing geriatric population; and growing demand for non-invasive aesthetic procedures.

According to the American Society of Plastic Surgeons (ASPS), in 2020, plastic surgeons stopped performing elective surgical procedures for an average of 8.1 weeks in 2020 due to COVID-19, or 15% of the year, which indicates the decline in the total number of procedures performed. Moreover, in 2020, minimally invasive cosmetic procedures decreased slightly more than surgical procedures (16% vs. 14%) during stay-at-home orders, dropping for the first time in four years. Such instances adversely impacted the market's growth rate in the initial phase of the pandemic. However, the recommencement of elective procedures and the reopening of cosmetic centers across the region are projected to help boost the market growth rate to its pre-pandemic levels.

Likewise, in Canada, the growing geriatric population is fueling the market's growth. As per the Statistics Canada 2021 census, there were around 7,021,430 people aged 65 years or above, out of which 3,224,680 were males and 3,796,750 were females. The demand for aesthetic fillers is expected to increase due to increased attention to geriatric aesthetics among this age group.

The presence of key players in United States and the launch of new products in the market gives the country an edge in the global market. In January 2020, Revance Therapeutics reported that a transformative aesthetics portfolio transaction with an exclusive United States distribution agreement for Food and Drug Administration-approved dermal fillers from Teoxane SA was completed. TEOXANE SA RHA portfolio is one of the first FDA-approved dermal fillers for correcting dynamic wrinkles.

Thus, with the abovementioned factors, the region is expected to witness rapid growth over the forecast period.

Facial Injectables Market Competitive Analysis

The facial injectables market is moderately competitive. The key players present in the market are developing collaborations and product launch strategies to address the unmet aesthetic needs. As a result, the market for facial injectables is growing due to the availability of new and improved options for physicians. The companies also focus on expanding their presence in emerging markets and maintaining strong distributor relationships. Some market players include AbbVie Inc. (Allergan Plc), Ipsen SA, Medytox Inc., Merz Pharma, and Sinclair Pharma Plc, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Aesthetic Consciousness and Number of Cosmetic Procedures
    • 4.2.2 Introduction of Cost-effective Facial Injectable
    • 4.2.3 Ageing Population
  • 4.3 Market Restraints
    • 4.3.1 Side-effects of Available Products Limiting Adoption
    • 4.3.2 Lack of Reimbursement Policies Supporting Cosmetic Procedures
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Type
    • 5.1.1 Wrinkle Relaxers
      • 5.1.1.1 Botulinum Toxin
    • 5.1.2 Dermal Fillers
      • 5.1.2.1 Collagen
      • 5.1.2.2 Hyaluronic Acid
      • 5.1.2.3 Fat Injection
      • 5.1.2.4 Polylactic Acid
      • 5.1.2.5 Polymethyl-methacrylate Microspheres (PMMA)
      • 5.1.2.6 Calcium Hydroxylapatite
      • 5.1.2.7 Other Dermal Fillers (Polyalkylimide etc.)
  • 5.2 By Application
    • 5.2.1 Facial Line Correction
    • 5.2.2 Lip Augmentation
    • 5.2.3 Face Lift
    • 5.2.4 Acne Scar Treatment
    • 5.2.5 Lipoatrophy Treatment
    • 5.2.6 Other Applications (Chin augmentation and Earlobe Rejuvenation etc.)
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AbbVie Inc (Allergan Plc)
    • 6.1.2 Anika Therapeutics Inc.
    • 6.1.3 Ipsen SA
    • 6.1.4 Medytox Inc.
    • 6.1.5 Merz Pharma
    • 6.1.6 Galderma Pharma SA
    • 6.1.7 Sanofi SA
    • 6.1.8 Sinclair Pharma Plc
    • 6.1.9 Suneva Medical Inc.
    • 6.1.10 Alphaeon Corporation (Teoxane Laboratories)
    • 6.1.11 Bloomage Biotechnology (Laboratories Vivacy SAS)
    • 6.1.12 SciVision Biotech Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS